Cigna Says It Is Not Pursuing Deal With Rival Humana

Cigna Group (CI.N), opens new tab said on Monday it is not pursuing a combination with rival health insurer Humana (HUM.N), opens new tab, days after Donald Trump’s reelection as U.S. president raised investor hopes that any merger would face far less antitrust scrutiny.

Humana shares rose after Tuesday’s election as investors bet on an easier antitrust review for any mega-merger during a Trump administration, analysts said.

On Monday, Humana shares fell 4% to $276.44 in early trading, while Cigna was up more than 7% at $343.53.

“Cigna’s latest clarification certainly puts the possibility of such a deal to bed,” Oppenheimer analyst Michael Wiederhorn said in a research note. Humana’s stock will remain under pressure following the news, he added.

The company in its release said it remains focused on acquisitions that are “strategically aligned, financially attractive and have a high probability to close.”

Humana did not immediately respond to a Reuters request for comment.

Bloomberg News reported in October that Cigna had revived efforts to merge with Humana. That came after Reuters reported last year that Cigna had ended its attempt to negotiate an acquisition after the pair failed to agree on a price.

Cigna also said it expects to actively repurchase shares in the fourth quarter and in 2025. The company said it was making the announcement ahead of meetings with investors and analysts over the next several weeks.

Morningstar analyst Julie Utterback called Cigna’s announcement unusual and said the move was aimed at removing pressure on its stock.

“With the Republican win last week, there was speculation by investors that the antitrust concerns may decline enough to make the deal possible,” Utterback said.

Cigna, which manages employer-sponsored healthcare plans and runs a pharmacy benefit manager, is in the process of selling its Medicare Advantage business, which manages government-backed health insurance for people aged 65 and older.

Last month, Cigna CEO David Cordani described the Medicare Advantage market as highly disrupted and said the company was focused on share buybacks.

 

 

Source Link

Recommended Articles

State PBM laws Face ERISA Preemption Challenges in Court

States seeking to limit the power of pharmacy benefit managers are running into legal roadblocks. Every state, as well as the federal government, has enacted PBM legislation over the last decade to rein in an industry accused of anticompetitive business practices. Those efforts have seen mixed results as agencies struggle to enforce requirements and courts ...

Read More

Employer Health Cost Crunch Is Worse Than Projected

There’s new evidence that double-digit health cost increases were hitting employers well before the forecasts of big spikes for 2027 — forcing big changes in workplace coverage for millions of Americans. Why it matters: The findings offer a higher-resolution view of how much health spending is putting a drag on the labor market and increasing ...

Read More

HHS Finalizes Changes To HIPAA Privacy Rule

HHS' Office for Civil Rights finalized a HIPAA privacy rule change cutting the protected health information request response window to 15 calendar days. The final regulation clarifies individuals can retrieve electronic PHI through health apps when entities can support that format.

Read More

Sutter Health-Allina Health Deal Clears Key Hurdle

Sutter Health and Allina Health have achieved a milestone in their plan to merge. The health systems agreed to invest $2.15 billion as part of a 10-year oversight arrangement that Minnesota Attorney General Keith Ellison (D) announced Monday. The deal has been under state review for months. Under terms of the agreement, Sacramento, California-based Sutter ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square